In 2012, we reported encouraging results with alirocumab from phase 2, demonstrating that alirocumab can lower LDL-C by about 70% on top of statins and bring almost 100% of patients to their LDL-C ...
Statins, a class of cholesterol-lowering drugs, have no effect on kidney function, a research team led by the University of Iowa has found.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback